Clinical trials: Mental Depression
Major Depressive Disorder
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD.
- Trial name
- NCT00644358
- Testing
- vilazodone
- Where
- 38 sites in United States
- Volunteers
- 616 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
The purpose of the study is to explore the Tolerability and Safety of the H-Coil deep Transcranial Magnetic Stimulation (TMS) in combination with Serotonin Selective Reuptake Inhibitor (SSRI) for Subjects with Major Depression…
- Trial name
- NCT01361815
- Testing
- H-Coil Deep TMS in combination with SSRIs
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Brainsway
Depression, Bipolar Disorder
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
- Trial name
- NCT03403790
- Testing
- Quetiapine
- Where
- 47 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen
Major Depressive Disorder
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
- Trial name
- NCT00905424
- Testing
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Where
- 15 sites in United States
- Volunteers
- 246 people
- Sponsor
- Shire
Major Depressive Disorder, Anxiety
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.
- Trial name
- NCT00621270
- Testing
- BCI-540
- Where
- 16 sites in Canada
- Volunteers
- 115 people
- Sponsor
- BrainCells Inc.
Bipolar Depression, Bipolar Disorder
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models. This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses…
- Trial name
- NCT00908154
- Testing
- GSK1014802
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biogen
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder
Seasonal Affective Depression (SAD) Study
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
- Trial name
- NCT00069459
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Depression, Panic Disorder
Special Investigation Of Long Term Use Of Sertraline.
Special investigation of long term use of sertraline, 52 Week Observation, Long-Term Safety. The objective of this "Special investigation" is to collect information about 1) adverse drug reactions not expected from the LPD…
- Trial name
- NCT00605813
- Testing
- Sertraline hydrochloride
- Volunteers
- 542 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety Depression
Probiotics Regulate Intestinal Health and Alleviate Anxiety
This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.
- Trial name
- NCT07353320
- Testing
- probiotics group
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With MDD
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03560518
- Testing
- Rapastinel
- Where
- 40 sites in United States
- Volunteers
- 439 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Respiratory Depression, Respiratory Failure
Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes
Assessment of AnchorFast Guard Oral Endotracheal Tube Fastener on Patients Intubated with Oral Endotracheal Tubes with Subglottic Suction
- Conditions
- Respiratory Depression, Respiratory Failure, Ventilatory Depression
- Trial name
- NCT02760927
- Testing
- Endotracheal Tube Fastener
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Hollister Incorporated
Depressive Disorder, Major
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)
- Trial name
- NCT00057213
- Testing
- Radafaxine
- Where
- 21 sites in United States
- Volunteers
- 367 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Bipolar, Bipolar Disorder (BD)
Transcranial Photobiomodulation for Bipolar Depression
This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression.
- Conditions
- Bipolar, Bipolar Disorder (BD), Bipolar Disorder Depression
- Trial name
- NCT07510646
- Testing
- Vielight Neuro Rx Gamma
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Vielight Inc.
Major Depression Disorder
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
- Trial name
- NCT02400346
- Testing
- Adjunct brexpiprazole, ADT
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 132 people
- Sponsor
- H. Lundbeck A/S
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Drug Abuse
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
The prevalence estimates for specific mental disorders and illicit drugs have been separately reported in U.S. government surveys.
- Conditions
- Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder
- Trial name
- NCT02476877
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.
Major Depressive Disorder
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
- Trial name
- EXTEND (NCT06605105)
- Testing
- CYB003
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 468 people
- Sponsor
- Cybin IRL Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.